Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
Through the use of ribosome profiling, our findings indicate mTOR inhibition as a novel combination therapy for partnering with the translation inhibitor omacetaxine in the treatment of multiple myeloma.
Authors
- Beau M. Idler (ORCID: https://orcid.org/0000-0003-4895-2185)
- Katherine F. Vaeth (ORCID: https://orcid.org/0000-0002-0127-6629)
- Zachary J. Walker (ORCID: https://orcid.org/0009-0002-1384-3309)
- Amber Baldwin (ORCID: https://orcid.org/0000-0002-7346-3052)
- Kady A. Dennis (ORCID: https://orcid.org/0000-0003-0628-7578)
- Lauren T. Reiman (ORCID: https://orcid.org/0000-0003-1817-1599)
- Denis Ohlstrom (ORCID: https://orcid.org/0000-0003-1920-6319)
- Daniel W. Sherbenou (ORCID: https://orcid.org/0000-0003-3013-7174)
- Brett M. Stevens (ORCID: https://orcid.org/0000-0002-9346-903X)
- Neelanjan Mukherjee (ORCID: https://orcid.org/0000-0003-0017-1400)
- Kate Matlin (ORCID: https://orcid.org/0000-0002-4011-7858)
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- Mayo Clinic in Arizona (US)
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Molecular Cancer Research
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1158/1541-7786.mcr-24-0444
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00